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Abstract
The role of circulating miRNAs (c-miRNAs) in carcinogenesis
has garnered considerable scientiﬁc interest. miRNAs may con-
tribute actively to cancer development and progression, making
them potential targets for cancer prevention and therapy.
Lifestyle factors such as physical activity (PA) have been shown
to alter c-miRNA expression, but the subsequent impact on
cancer risk and prognosis is unknown. To provide a better
understanding of how PA reduces the risk of cancer incidence
and improves patient outcomes, we conducted a review of the
impact of PA on c-miRNA expression, which includes a com-
prehensive synthesis of studies examining the impacts of acute
and chronic exercise on expression of c-miRNAs. While the
variability in methods used to assess miRNA expression creates
challenges in comparing and/or synthesizing the literature,
results to date suggest that the circulating form of several
miRNAs known for playing a role in cancer (c-miR-133,
c-miR-221/222, c-miR-126, and c-let-7) are altered by both acute
and chronic PA. Additional research should develop standardized
procedures for assessing both c-miRNA and PA measurement to
improve the comparability of research results regarding the
direction and amplitude of changes in c-miRNAs in response
to PA. Cancer Epidemiol Biomarkers Prev; 27(1); 11–24. 2017 AACR.
Introduction
miRNAs are implicated in the etiology of various diseases,
including cancer (1), and understanding their biologic char-
acteristics has led to novel insights for cancer diagnosis, treat-
ment, and prognosis (2). miRNAs are considered to be stable
in healthy individuals, but external factors including lifestyle
can impact their expression. Several studies have reported
that physical activity (PA) can modulate miRNA expression
(3–5). The impact of PA on reducing cancer risk and improving
cancer progression has been well documented, but the exact
mechanisms underlying these relations are not yet completely
understood (6, 7). A better understanding of altered expression
and function of miRNAs in response to various forms of PA
could assist in clarifying the role of PA in cancer prevention and
prognosis.
miRNAs and cancer
miRNAs are a class of small noncoding RNAs that regulate
gene expression posttranscriptionally, either by mRNA cleavage,
mRNA destabilization, or inhibition of translation (8). Since
the ﬁrst miRNA was discovered by Lee and colleagues in 1993,
more than 2,500 human miRNA sequences have been identiﬁed
(miRBase; ref. 9). This rapid expansion of discovery can be
partially explained by the broad importance ofmiRNAs in regular
bodily functions. miRNAs are predicted to modulate more than
60% of protein-coding genes (10) and are involved in numerous
integral cellular processes, including development, proliferation,
metabolism, and signal transduction (11, 12). Given their regu-
latory importance, it is not surprising that miRNAs are widely
implicated in carcinogenesis and progression. The mechanistic
role of miRNAs in cancer was ﬁrst discussed by Johnson and
colleagues in 2005 (13) and the number of studies has been
rapidly expanding ever since. In both solid and hematologic
tumors, numerous miRNAs have been found to be altered, and
their expression is associated with the severity and stage at
diagnosis (14). In breast cancer, for example, several miRNAs
have been observed as very early biomarkers of this disease (15).
The role of miRNAs in carcinogenesis and cancer progression
is twofold. Both in vivo and in vitro studies have demonstrated
they target either tumor suppressors or oncogenes (16). Expres-
sion of particular miRNAs can downregulate various onco-
genes or reexpress tumor suppressor genes, leading to tumor
suppression, whereas upregulation of other miRNAs, also
referred to as oncomiRs, inhibits tumor suppressor genes or
overexpress oncogenes, thereby promoting tumor cell prolifer-
ation and metastasis (16).
miRNAs are found in tissues and organs and are also released
into the circulation in a remarkably stable form (17). The
1Movement, Sport and Health Sciences Laboratory, University Rennes 2, ENS
Rennes, Bruz, France; University Rennes 1, Rennes, France. 2Department of
Oncology, McMaster University, Hamilton Ontario, Canada. 3Department of
Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta
Health Services, Calgary, Alberta, Canada. 4Department of Oncology, Cumming
School of Medicine, University of Calgary, Calgary, Alberta, Canada. 5Depart-
ment of CommunityHealth Sciences, Cumming School ofMedicine, University of
Calgary, Calgary, Alberta, Canada.
Corresponding Author: Darren Brenner, Department of Cancer Epidemiology
and Prevention Research, CancerControl Alberta, Alberta Health Services, Holy
Cross Centre, Room 513, Box ACB, 2210 2nd Street S.W., Calgary, Alberta T2S
3C3, Canada. Phone: 403-698-8178; Fax: 403-476-2654; E-mail:
darren.brenner@albertahealthservices.ca
doi: 10.1158/1055-9965.EPI-16-0969
2017 American Association for Cancer Research.
Cancer
Epidemiology,
Biomarkers
& Prevention
www.aacrjournals.org 11
on August 27, 2019. © 2018 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Published OnlineFirst November 15, 2017; DOI: 10.1158/1055-9965.EPI-16-0969 
expression of those c-miRNAs has been found to be modiﬁed in
numerous cancers including, but not limited to, colorectal,
prostate, breast, hepatocellular, gastric, and head and neck
cancers (1, 18–24). Altered c-miRNA expression was ﬁrst
observed in B-cell lymphoma patients by Lawrie and colleagues
in 2008 (25) and it is now established that, on average, the
expression of 100 c-miRNAs are altered in each cancer type.
More importantly, the discovery of c-miRNAs in body ﬂuids
resulted in the implication of new possible pathways through
which miRNAs may impact tumor development and progres-
sion, and led to novel insights for their use as therapeutic tools
for cancer (26, 27).
miRNAs as potential mediators of the association between
physical activity and cancer
PA has been shown to reduce cancer risk and progression
(6, 28–31). Multiple hypothesized biologic mechanisms have
been proposed to explain these beneﬁts (6, 29, 32) including
reductions in chronic inﬂammation, regulation of metabolic
factors, changes in insulin resistance, enhanced immune system
function, and levels of circulating sex hormones, myokines, or
adipokines (6, 29, 32, 33). The exact mechanisms, however,
whereby PA alters cancer risk and progression at various cancer
sites are not fully understood and additional pathways are likely.
As miRNAs are now well recognized for playing important roles
in carcinogenesis and cancer outcomes, they could be involved
in the PA-related beneﬁts toward cancer.
The impact of PA on miRNAs has been investigated by several
research groups, but mainly in the context of physical perfor-
mance, muscle pathogenesis, and muscular dysfunction related
to aging, as well as in muscle disorders associated with diabetes,
cancer, and inﬂammation (3). The majority of the miRNAs
shown to be altered by either acute or chronic exercise in these
studies are muscle-speciﬁc miRNAs, also called myomiRs.
miRNAs are differentially expressed within various organs, and
if a miRNA is expressed more than 20-fold in a speciﬁc tissue
compared with the mean of its expression in other tissues, it is
thus considered as a tissue-speciﬁc miRNA (34). The expression
of a variety of miRNAs, and particularly myomiRs, is modulated
by PA within muscle tissues (4, 35) as well as in plasma (5).
Zacharewicz and colleagues (4) have published a detailed
review on miRNA expression within muscles in response to PA.
Here we restrict our review to miRNA expression in blood
following acute or chronic PA.
c-miRNAs are currently being extensively studied due to
several advantages from a clinical and etiologic perspective
including a remarkable stability in the circulation, resistance
to RNase activity (36), and preservation through multiple
freeze–thaw cycles (37). Consequently, c-miRNAs can be easily
evaluated by standard and relatively inexpensive qRT-PCR
techniques, even in low concentrations (38), and their mea-
surement is a noninvasive procedure (39). This is in stark
contrast to the analysis of miRNA expression within speciﬁc
tissues, which require biopsies. On the basis of these differ-
ences, c-miRNAs measured from stored blood samples will
prove advantageous in the conduct of large epidemiologic
studies of PA-related cancer etiology. For these reasons, in this
review, we focused on the role of c-miRNAs as an underlying
mechanism mediating PA's beneﬁts against cancer through the
exploration of potential links between PA-induced c-miRNA
modulation and cancer-related c-miRNA expression.
The majority of c-miRNAs are derived from leukocytes and
endothelial cells (40) but they can also originate from organs
exposed to high blood ﬂow (3). When exercising, the blood
ﬂow is signiﬁcantly elevated, with up to 80-fold blood ﬂow
increase in times of high physical output (41, 42), leading to
expression changes in miRNAs originating from various organs
(43–45), and in particular from skeletal muscles. The release of
miRNAs in the blood circulation can originate from destroyed
tissues (46, 47), especially if the exercise load is great (48).
However, increases in the expression of c-miRNAs have also
been reported in the absence of cell damage markers in plasma
(49). miRNAs can, in fact, be exported by active transport
systems, either encapsulated in extracellular vesicles (such as
exosomes; refs. 46, 50, 51), or associated with protein or lipid-
based complexes [e.g., Argonaute2 (AGO2), high-density lipo-
proteins (HDL), and low-density lipoproteins (LDL); refs. 36,
52–54]. Importantly, increasing evidence shows that miRNAs,
through their circulating form, can be transported from donor
cells to recipient cells, where they exert their functions (18, 54).
c-miRNAs are thus being recognized as important components
in intercellular communication (53, 55, 56), and have notably
been demonstrated to play key roles in crucial cellular process-
es, such as apoptosis, proliferation, metastasis, and immunity
(56, 57). For example, exosomal-miR-105 secreted by breast
cancer cells and transferred to endothelial cells have been
shown to promote metastasis (58).
Materials and Methods
We conducted a literature search up to March of 2016 in
PubMed using the following search strategy: "miRNAs AND
exercise" or "miRNAs AND physical activity" or "microRNAs
AND exercise" or "microRNAs AND physical activity." Only
studies conducted in humans containing data measuring
c-miRNAs were included.We did not employ aminimum sample
size threshold and studies with small numbers of participants
were also included, as the total number of studies meeting our
inclusion criteria was relatively small. Studies examining popu-
lations with disease were excluded, and all studies included in
the review presented measurements among healthy subjects as
underlying diseases may impact c-miRNAs. To our knowledge,
there are no data on the effect of PA on c-miRNA expression in
patients with cancer. One study has investigated the impact of
PA on miRNA expression within tumor tissue based on an
animal model, and is included in the Discussion section. We
also analyzed reference lists of the identiﬁed studies for addi-
tional relevant articles. The title and abstract were examined,
and full text was obtained if the article seemed eligible. No
period or language restrictions were applied. We compiled
the results from studies investigating c-miRNA expression in
response to a single bout of PA (acute PA) in either normally
active individuals (Table 1) or trained subjects (Table 2) as well
as the impact of a training period and/or regular PA (chronic
PA) on basal c-miRNA expression (Table 3).
Tables 1 and 2 include details on study (design, sample size,
timing of blood draws), participant (age, gender, PA level), and
protocol characteristics [training program if any, type of exercise
(resistance or endurance exercise)]. Included in these tables are
descriptions of the number of miRNAs screened, number of
miRNAs altered by PA, miRNAs measured but not altered, and
undetectable or unreliable miRNAs.
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With regards to the type of exercise, we considered predomi-
nantly endurance exercises as exercises involving the whole body
and increasing oxidative capacity and aerobic endurance (e.g., a
marathon run),while resistance exerciseswere deﬁned as exercises
using machines, weights, or even individuals' body weight to
stimulate muscle hypertrophy and increase muscular strength or
power (e.g., leg press, squats, pull-ups). We highlight the distinc-
tions between normally active and "trained" participants, based
on the information provided by the studies. We considered the
subjects trained if: (i) the subjects underwent a speciﬁc training
program described in the study; (ii) a large bout of exercise, such
as a marathon run, was included in the protocol as undergoing
such an effort implies previous training (even though not always
speciﬁed in the reviewed studies); (iii) the authors stated that the
participants were "trained individuals" and/or part of a compet-
itive program. We considered the subjects "untrained" or "nor-
mally active" if the participants engaged in recreational activity
4 hours per week and/or if speciﬁed in the study. In total, we
included 5 studies examining normally active individuals and 10
studies investigating trained individuals, according to our criteria.
To facilitate comparisons across studies, we present the data
for c-miRNAs that were examined in multiple studies. We ﬁrst
synthesize and discuss the results obtained for c-miRNA expres-
sion following acute PA, followed by a discussion and synthesis
of results examining basal miRNA expression in response to
chronic PA.
PA has also been shown tomodulatemiRNA expressionwithin
peripheral blood mononuclear cells (PBMC). PBMCs are leuko-
cytes with a round nucleus, and comprise lymphocytes (T cells, B
cells, and natural killer cells), monocytes, and dendritic cells (59).
Similar to c-miRNAs, PBMC miRNAs can easily be detected by
standard qRT-PCR techniques, but it remains controversial
whether their expression is similar or not to whole bloodmiRNAs
(60, 61). Thus, even though two different research groups found
an impact of acute PA in circulating leukocytes (62–65), those
results are not discussed in this review.
Results
We have identiﬁed a total number of 16 studies in our review,
which are displayed in Tables 1–3. Among these studies, 14
investigated c-miRNA expression in response to a single bout of
exercise (48, 49, 65–76), and six (49, 66, 71, 75, 77, 78) evaluated
the impact of chronic exercise on c-miRNA expression.
Impact of acute physical activity on c-miRNA expression
Acute PA refers to a single isolated PA session. It is clear that a
single bout of PA alters expression of several c-miRNAs shortly
after its completion (Tables 1 and 2). However, the modalities of
PA [frequency, intensity, timing and type (FITT)] and the indivi-
dual's physical ﬁtness levels (trained or untrained) may impact
those changes. Modiﬁcations in several c-miRNAs are not always
observed immediately after PA, but are seen only after 2–3 hours
of rest. For example, Banzet and colleagues reported no changes in
miRNA expression immediately after the completion of a single
bout of eccentric exercise (30 minutes downhill walking) but
observed an increase in miR-1, miR-133a, miR-133b, miR-499-
5p, andmiR-208b 6 hours post bouts of PA (68). These c-miRNAs
then returned to baseline expression after periods of inactivity,
whichhas been reported to be relatively slow in some studies (66–
68, 70, 72). For example, decreased expression of c-miR-221 was
still observed by Sawada and colleagues 3 days postcompletion of
a resistance exercise session (67).
Muscle- or cardiac-speciﬁcmiRNAs. In healthy individuals,muscle-
or cardiac speciﬁc miR-1, miR-133, miR-206, miR-499, and miR-
208 are expressed at low levels in the circulation, whereas miR-
486 is generally found in higher concentrations (74, 79). In
response to PA, several studies have shown an increase in the
circulating forms of miR-1, miR-133, miR-206, miR-208, and
miR-499 immediately after the completion of various PA modal-
ities (FITT; refs. 48, 68, 70, 72, 73, 75, 76), and a decrease in miR-
486 (66). It canbenoted that speciﬁc exercisemodalities appear to
impact changes in miRNA levels. Banzet and colleagues found
different c-miRNA expression patterns in normally active parti-
cipants who underwent a downhill walk versus others who
completed an uphill walk (68). Downhill walking is considered
an eccentric exercise as the muscles actively lengthen during this
effort, whereas uphill walking induces active shortening of the
muscles and is thus considered a concentric exercise. Interestingly,
Banzet and colleagues found signiﬁcantly higher muscle/cardiac
speciﬁc c-miRNA expression for participants who walked down-
hill compared with subjects walking uphill (68). Thus, these data
suggest that the type of muscle contraction involved in the
exercises impacts c-miRNA expression. Furthermore, data from
various studies also suggests thatmuscle/cardiac c-miRNAs can be
differentially expressed depending on PA's intensity. For example,
when looking at c-miR-133, Uhlemann and colleagues showed
that modiﬁcations in c-miR-133 expression in response to PA
were correlated with phosphocreatine kinase (CPK) activity, a
marker for muscle damages: the more damaging the exercise was,
the most altered c-miR-133 expression was (48).
Modulations in muscle/cardiac c-miRNA expression postexer-
cise appear to be temporary, yet the exact delay before a return to
baseline values is unclear. When examining measures taken one
day postexercise, most studies showed that muscle and cardiac
speciﬁc c-miRNAs had returned to their basal value. Others,
however, reported a decrease in expression of those c-miRNAs
compared to immediately after exercise, but still signiﬁcantly
elevated compared to baseline values. Focusing on c-miR-1 for
example, four studies found similar expression of this c-miRNA
between preexercise and 24 hours postexercise (49, 68, 75, 76),
while one other observed signiﬁcantly higher expression com-
pared with baseline value (but attenuated from expression mea-
sured immediately after exercise; ref. 70).
Interestingly, high interindividual variation in c-miR-499
expression has been reported in response to an acute bout of
endurance exercise in two different studies (68, 72) which sug-
gests that c-miR-499 is highly dependent on participants' char-
acteristics, notably their training status. miR-499 is a cardiac-
speciﬁc miRNA and studies have shown its circulating form may
represent a marker of myocardial injury (80–84). Strenuous
exercises such as marathon running can induce transient myo-
cardial injuries (85–88), this risk being higher in less trained
individuals (87, 89). Therefore, the interindividual variation
observed in c-miR-499 expression following amarathon runmay
reﬂect variation in training among participants, and/or cardiac
muscle exhaustion.
Other circulating miRNAs. Non muscle- or cardiac-speciﬁc
c-miRNAs have also been reported to be impacted by acute PA,
but the exact direction and magnitude of those changes remain
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unclear. Two different research groups observed an upregulation
of c-miR-126, an endothelial-speciﬁc miRNA involved in angio-
genesis (90), immediately after a single bout of PA (48, 72), while
no statistical differences in c-miR-126 expression pre- andpost-PA
have also been reported (48, 69). Interestingly, Uhlemann and
colleagues measured c-miR-126 expression before and after an
acute bout of PA: subjects were either trained or untrained and the
exercises which had to be completed varied among protocols in
type, duration, and intensity (48). They observed an upregulation
in c-miR-126 in response to a single maximal symptom–limited
test performed by healthy individuals, as well as in trained men
who underwent 4 hours of bicycling at 70% of their anaerobic
threshold, and in trained runners who completed a marathon.
However, Uhlemann and colleagues also reported no signiﬁcant
difference in c-miR-126 expression in trained subjects who per-
formed a resistance training session compared with basal values
(48). As miR-126 is an endothelial-speciﬁc miRNA, the authors
explained the increase in c-miR-126 expression following acute
exercise observed in three of their protocols by exercise-induced
endothelial damages, while they suggested that the resistance
exercise session, which resulted in unaltered c-miR-126 expres-
sion, did not cause such damages (48).
c-miR-146a, a miRNA known for playing a role in inﬂamma-
tion and immunity (91, 92) has also been found to be altered by
acute PA; however, the effects appear to be highly dependent on
the type of activity intervention. Two studies have reported an
upregulation of this c-miRNA in response to a single bout of
endurance exercise in trained individuals (49, 72), but Nielsen
and colleagues observed opposite results with a decrease in
c-miR-146a in response to a similar type of PA in normally active
subjects (71). In contrast, Van Craenenbroeck and colleagues
reported no change in c-miR-146a expression in response to a
single maximal symptom–limited test, while Sawada and collea-
gues measured no alteration in c-miR-146a expression in healthy
men immediately after they performed resistance exercise session
but found a decrease in its expression three days postexercise (67).
Interestingly, in trained athletes, Baggish and colleagues found an
upregulation miR-146a in response to an acute bout of PA both
before and after a training program, the magnitude of the eleva-
tion being higher after completion of the training program (49).
Similarily, changes in the circulating expression of miR-221
and miR-222, important players in vascular biology (93), have
been reported, but high variations can be found between the
studies (49, 67, 71). In response to a 60-minute cycle ergometer
exercise bout below anaerobic threshold, c-miR-221 has been
found to be downregulated in normally active participants by
Nielsen and colleagues (71), as opposed to Baggish and collea-
gues who showed an upregulation of c-miR-221 expression in
trained individuals following an acute exhaustive cycling exercise
(49). When assessing the impact of a short exhaustive bout of PA
on the c-miRNA expression, Sawada and colleagues did not report
any changes immediately after PA completion, but found a
decrease three days later (67). c-miR-222 expression in response
to an acute bout of PA has only been investigated by two different
studies: one of them showed an upregulation of this c-miRNA in
trainedmenundergoing an exhaustive bout of exercise (49),while
the other one reported no change in its expression between before
and after a resistance exercise session (67). The differences
observed between studies are likely attributable to differences in
protocols, suggesting that alterations of c-miRNAs in response to
acute PA are dependent on the dose and type of exercise (FIIT) as
well as participants' characteristics (e.g., age, gender, ﬁtness level,
health status, personal history, diet, smoking habits, etc.).
Impact of chronic physical activity on c-miRNA expression
Chronic PA is deﬁned as regular PA done over an extended time
period (a minimum of several weeks). Interestingly, contrary to
what is observed for c-miRNA expression following an acute bout
of PA (Tables 1 and 2), there is a general trend for a down-
regulation of c-miRNAs expression in response to chronic PA
(Table 3). Among the six different studies investigating the impact
of chronic PA on resting expression of c-miRNAs we included in
our review, four were intervention trials (49, 66, 71, 75) and two
were observational studies (77, 78). The blood samples analyzed
in those research projects were taken at rest, at least 12 hours after
the last training session.
Muscle- or cardiac-speciﬁc miRNAs. Cardiac- or muscle speciﬁc
c-miRNA expression changes in response to chronic PA are hard to
measure because of their low concentrations in humans at rest,
consequently, there are limited results thus far. For c-miR-1, one
study reported no change between its resting expression before
and after a 10-week marathon training period in either trained
or untrained individuals (75), whereas two other research
groups found its expression too low to interpret its measurement
(66, 78). A trend towards a decrease in c-miR-133 expression in
response to a supervised training on a cycle ergometer was
found by Nielsen and colleagues (71), while other studies
reported no changes (49, 75) or nondetectable amounts for the
quantiﬁcation of c-miR-133 (66, 78). Several studies measured
the resting expression of c-miR-206 (66, 78), c-miR-208 (66), and
c-miR-499 (66, 78) before and after a training period, but their
expressions were too low to be interpreted. Finally, Aoi and
colleagues found that a 4-week cycling program downregulates
c-miR-486 basal expression (66).
Other circulating miRNAs.When evaluating c-let-7d expression, a
miRNA that has a crucial role in cell division and differentiation
(94, 95), Nielsen and colleagues showed a downregulation of
its baseline expression after a 12-week training period (71) while
Bye and colleagues' observational study (77) showed that
subjects with high maximal oxygen uptake ( _VO2max; 145.2 
20.7 mL/kg0.75/min) had a lower c-let-7d expression compared
with individuals engaging in similar activity levels but with
lower _VO2max (101.1  18.0 mL/kg0.75/min).
For c-miR-21, Nielsen and colleagues reported that baseline
expression was decreased after chronic PA (71), while the results
obtained fromBye and colleagues' observational study shows that
independently of activity levels, individuals with high _VO2max
have decreased c-miR-21 basal expression comparedwith subjects
with lower _VO2max (77).However, Baggish and colleagues found
an upregulation of c-miR-21 after 13 weeks of rowing training,
while Wardle and colleagues reported no alteration in expression
between athletes (endurance or resistance trained) and controls,
but showed a signiﬁcant increase in resistance trained individuals
when compared with endurance athletes (72, 78).
c-miR-221 and c-miR-222 expression in response to chronic PA
remains unclear. Baggish and colleagues reported increased
expression of c-miR-222 after a 13-week training program (72),
in line with Wardle and colleagues' ﬁndings when comparing
endurance trained athletes with control individuals (78).
However, Wardle and colleagues found a downregulation of
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c-miR-222 in resistance trained athletes, and Bye and colleagues'
reported a decrease in c-miR-222 expression in individuals with
high _VO2maxwhen comparedwith subjectswith a lower _VO2max
(77, 78). Similarly, various results have been found for the
changes of c-miR-221 expression in response to chronic PA:
Baggish and colleagues reported an increase in its baseline expres-
sion after a training period (72), whereas Wardle and colleagues
found no statistical differences between trained athletes
(endurance or resistance) and controls, but a downregulation
in resistance-trained athletes when compared with endurance-
trained athletes (78).
Discussion
Potential impact of PA-induced c-miRNA changes on cancer
risk, progression, and treatment
Overall, the current results available from the scientiﬁc
literature suggest that several c-miRNAs are impacted by acute
PA (miR-1, miR-133, miR-206, miR-208, miR-499, miR-486,
miR-126, miR-146, miR-221, and miR-222) and/or by chronic
PA (miR-133, miR-486, let-7d, miR-21, miR-222, and miR-221).
Importantly both acute PA and chronic PA appear to induce
changes in c-miRNA expression depending on exercise moda-
lities and individuals' ﬁtness status. While results to date are
promising and suggest a clear impact of PA onmiRNA expression,
comparisons between studies are challenging and efforts should
be devoted toward standardized protocols and procedures for
miRNA collection, analysis, and reporting.
The studies included in this review suggest that PA modulates
c-miRNA expression in healthy individuals. Several studies
have also observed that PA can alter c-miRNA expression within
disease populations such as patients with chronic kidney dis-
eases (69) and prediabetic individuals (96). To our knowledge,
however, no data exist regarding the impact of PA on miRNA in
patients with cancer. PA also appears to be able to inﬂuence
miRNA expression within organs other than skeletal muscles
(97, 98). Taken together, these elements suggest that PA may
inﬂuence c-miRNA expression in cancer patients, perhaps via
c-miRNA intercellular communication. This hypothesized
mechanism is illustrated in Fig. 1.
Throughout this section,wediscuss howmodulation of speciﬁc
c-miRNA expression by PAmight impact cancer risk, progression,
and treatments, and provide some examples of promising early
ﬁndings. Figure 2 presents hypothesized examples of how PA
could impact cancer via c-miRNA modulation using c-miR-133,
c-miR-221/222, c-miR-126, and c-let-7.
Impact of miRNAs on cancer risk and development. Multiple
miRNAs are involved in DNA repair, checkpoint functions,
tumor suppression, etc. (99), and their modulation by PA
might play an important role in cancer risk and progression.
For example, PA can alter c-miR-133 expression (48, 68, 70–73,
75, 76, 100), a well-known myoMiR participating in myoblast
differentiation, which has also been identiﬁed as a tumor
suppressor (101) in several cancers, including ovarian, colo-
rectal, bladder, breast, prostate, and gastric cancers (100, 102–
107). miR-133 has also been shown to be modiﬁed within
muscle tissues in response to acute and chronic PA. More
speciﬁcally, acute bouts of exercise seem to increase muscular
miR-133 expression (108, 109), while training tends to de-
crease expression (108). These data suggest that miR-133 can
translocate from muscle tissue to blood vessels, and that this
miRNA can impact cancer progression as depicted in Fig. 1.
Several studies suggest that miR-133 targets several oncogenes,
such as the EGFR (100) and the insulin-like growth factor 1
receptor (IGF1R; refs. 107, 110). When activated, those onco-
genes stimulate various pathways causing deregulation in sev-
eral cell processes, eventually leading to carcinogenesis. For
example, activation of EGFR pathway leads to the stimulation
of intracellular signaling cascades such as the MAPK/ERK path-
way, which plays a role in cell-cycle progression, differentia-
tion, proliferation, and apoptosis (111, 112). When activated,
the EGFR pathways also stimulate the PI3K/AKT cascade,
known for its crucial role in regulation of apoptosis and protein
synthesis (113, 114). An increase in c-miR-133 by PA originat-
ing from muscle tissue, may therefore impact tumor cells and
regulate target oncogenes and associated pathways.
Similarly, let-7 is a tumor suppressor and proapoptotic
miRNA (115) whose expression is decreased in numerous
cancers (116), and reported to be modulated in plasma by
Figure 1.
Hypothesized pathways of miRNA
transport from muscles to tumor cells
via the circulation. miRNAs can be
exported from one cell to another via
plasma through various active
transport systems including:
exosomes developed within
multivesicular bodies (MVB); released
into the blood circulation after fusion
of the MVBs with the plasma
membrane; transport through protein
or lipid-based complexes, such as
HDL, and delivered to recipient cells.
Abbreviations: MVB, multivesicular
body.
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exercise (71, 77). While no direct evidence was identiﬁed
in humans, in an animal model, breast tumor-bearing mice
who underwent 5 weeks of interval exercise training (tread-
mill running) had increased let-7 expression within the tumor
itself when compared with breast-tumor sedentary mice
(117). Let-7 is known for inhibiting mRNA translation of
well-known oncogenes, including the RAS family (HRAS,
KRAS, and NRAS; ref. 13) and c-MYC (refs. 118, 119). When
activated, Ras stimulates several signaling pathways, including
MAPK cascade and PI3K/AKT (120), thereby inﬂuencing many
cellular functions.
We must note the complex and often paradoxical role of
miRNAs, with several miRNAs exerting stimulatory as well as
inhibitory effects depending on cancer type or stage of the
disease (121–123). miR-221 and miR-222 for example have a
dual role: they can either act as tumor suppressors as onco-
genes. On one hand, miR-221 and miR-222 have been found
to relent cancer progression in several cancer types, and their
expression in the circulation have been found to be altered by
PA in several studies (49, 71, 72, 77, 78). In gastrointestinal
stromal tumors, for example, miR-221 and miR-222 are
thought to have prophylactic effects by negatively regulating
the stem cell factor receptor KIT, and are found underex-
pressed in tumors when compared with healthy tissues
(124–126). KIT is a receptor tyrosine-kinase (RTK), and its
activation leads to the stimulation of several intracellular
signaling pathways, including the STAT3, PI3K, phospholipase
C (PLC), and the MAPK cascade (127–129). KIT promotes cell
survival, proliferation, and motility (130), and its inhibition
by miR-221 and miR-222 therefore contributes to carcinogen-
esis suppression. Modulation of those miRNAs by PA could
thereby inhibit KIT activation, consequently lowering the risk
of developing cancer.
On the other hand, miR-222 and miR-221 have been shown
to act as oncomiRs in other cancer types. In lung and liver
cancer for example, these miRNAs have been shown to inhibit
the action of the PTEN, known to inhibit MAPK/ERK pathway,
and the tissue inhibitor of metalloproteinases-3 (TIMP3),
thereby enhancing cell proliferation and migration through
PI3K/AKT pathway (131). The dual role played by miR-222
and miR-221 suggest that clarifying the inﬂuence of exercise
modalities (endurance vs. resistance, short vs. long duration,
regular vs. irregular training, etc.), tissue and/or cancer site of
interest will be extremely important in subsequent research.
Impact of miRNAs on cancer invasion and metastasis. PA also
modulates c-miRNAs involved in cell proliferation, invasion
and metastasis (Fig. 2). For example, miR-21 is altered by re-
sistance and endurance training (71, 72, 78) and is also known
for participating in tumor invasion. In fact, in vitro studies have
shown that in several cancer types, miR-21 knockdown mice
displayed suppression of cell proliferation and tumor growth
(132), as well as reduced invasion and metastasis (132–134).
Furthermore miR-21 negatively regulates tumor suppressor
programmed cell death 4 (PDCD4; ref. 135) and downstream
signaling targets (136, 137) in colorectal cell lines. The results
in this review (Tables 1–3) suggest that acute exercise can
transiently upregulate c-miR-21 expression (65, 49), while
chronic exercise (which reﬂects physiologic adaptations) can
also lead to alterations in miR-21 expression within circulation
Figure 2.
Hypothesized mechanisms of action
of PA on cancer risk and progression
through c-miRNA modulation.
Multiple c-miRNAs (miR-126, miR-221/
222, miR-133, and Let-7) that impact
pathways involved in cancer risk and
progression have been shown to be
altered by PA.
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(71, 77); however, the inﬂuence of chronic PA is less clear. By
lowering miR-21 expression within cancer cells, PA may restore
PDCD4 and PTEN activation and limit cancer proliferation.
This is supported by literature that suggests PA is able to
modulate miR-21 within multiple tissues/ﬂuids, for example
muscle tissue in mice (138) as well as in plasma in healthy
human subjects (49, 65, 71, 77, 78), as well as in tumors of
breast tumor-bearing mice (Fig. 1; ref. 117).
The upregulation of c-miR-126 by acute PA (48, 72) might
also represent a pathway through which PA impacts cancer
progression. In breast cancer, miR-126 regulates the tumor
microenvironment composition by directly inhibiting stromal
cell–derived factor-1 alpha (CXCL12) expression and indirectly
suppressing chemokine ligand 2 (CCL2) expression in cancer
cells; ref. 139). These two chemokines play a role in recruit-
ing stromal cells to the primary tumor microenvironment
(140, 141), thereby leading to cancer cell invasion and metas-
tasis. Therefore, the increase in c-miR-126 expression in
response to acute PA followed by active transport into tumor
cells could lead to inhibition of CXCL12 and CCL2, conse-
quently suppressing cancer expansion by modifying the tumor
microenvironment composition (48).
Overall, PA-induced c-miRNA expression changes could have
the potential to impact tumorigenesis and cancer development.
Importantly, several studies suggest that reexpression of tumor
suppressor miRNAs within tumor tissues can inhibit tumor
growth, thereby representing a promising therapeutic tool
against cancer (18, 142–144). For example, reexpression of
let-7 within various tumor types have been proven to slow
cancer growth (94, 145–147) and is thus considered a prom-
ising tool against cancers underexpressing let-7 family mem-
bers (145, 148). Additional research, particularly large inter-
vention studies in populations of cancer patients, is needed to
determine the exact impact of PA on miRNA expression and
potential roles in cancer therapy.
Limitations of the research to date
Investigating c-miRNAs in response to PA presents several
challenges. First, to date, there are few studies that have compared
similar c-miRNAs using comparable methods to enable direct
comparisons across studies. Although some consistency has been
observed for several c-miRNAs such as miR-133 (48, 70, 72,
73, 75, 76), contradictory results have often been observed. This
inconsistency can largely be attributed to discrepancy in methods
across studies, including: (i) differences in sample collection; (ii)
postprocessing of samples, and (iii) theuse of serumor plasma for
miRNA extraction.
Different normalization strategies have been used between
the reviewed studies. The current results available on c-
miRNA expression changes in response to PA should therefore
be carefully interpreted. For example, Nielsen and colleagues
used a stable expressed c-miRNA to account for the biological
variation between samples, whereas Baggish and colleagues
used a synthetic spike in approach (71, 72). Some studies also
included a hemolysis control phase in the study design, as it
has been shown that hemolysis occurring during blood col-
lection has substantial impact on the miRNA content in
plasma/serum (149). This issue occurs because erythrocytes
contain numerous miRNAs that unavoidably will contami-
nate a plasma sample if the erythrocyte bursts during sam-
pling (150).
Another methodologic factor likely to impact the reliability of
the results obtained from the various studies reviewed here is the
fact that miRNA concentrations vary between serum and corre-
sponding plasma samples (151). Analyzing and comparing
miRNA expression from serum and plasma within or between
studies should be done carefully.
To date, miRNA expression in response to PA has mainly
been measured in the circulation and in muscles, but it would
also be interesting to study the changes in miRNA expression in
other tissues. More speciﬁcally, investigating miRNA expression
after PA in target tissues, and more speciﬁcally tumor tissues,
would provide novel data of how PA can impact cancer through
miRNA modulation. Tissue-speciﬁc approaches would also aid
in a better understanding of the role of c-miRNAs in speciﬁc
cancer sites that may result in the development of targeted
novel therapies.
Conclusions and future directions
PA represents a lifestyle behavior that inﬂuences the expres-
sion of several c-miRNAs, some of which have been associated
with carcinogenesis and cancer progression. Our results suggest
that alteration of miRNAs within the circulation is dependent on
the type/modality/frequency of exercise as well as on the parti-
cipants' characteristics. Furthermore, the evidence to date on c-
miRNA expression in response to PA is limited by small sample
sizes without standardized measures of miRNA or physical
activity. miRNAs appear to have a meaningful impact on cancer
risk and progression; however, the effect varies between cancer
types. Therefore, it appears essential to provide a better under-
standing of how various types of PA in a speciﬁc population
could impact c-miRNA expression: it could represent a useful
tool for healthcare practioners in establishing and monitoring
PA programs for patients with cancer.
Future research should focus on large epidemiologic studies
with standardized blood storage and collection as well as
standardized measures of c-miRNA expression and objective
measures of PA. Additional consistency is needed to provide
more meaningful conclusions as well as standardization of PA
measurement. Further investigation into the effects of PA on
miRNAs is necessary and could have implication both for
cancer prevention, treatment, and survival outcomes.
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